Skip to main content
BBOT
NASDAQ Life Sciences

BBOT Q3 Loss Narrows to $34.2M; Cash Runway Extended Into 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.18
Mkt Cap
$176.383M
52W Low
$1.98
52W High
$14.87
52W Position info
10% above low
Off High info
85% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

BBOT is trading near its 52-week low of $1.98 (10% above the low).

Summary

BridgeBio Oncology reported a narrower Q3 2026 loss of $34.2M and $315.3M in cash, extending its runway into 2029. BBO-8520 monotherapy posted a 63% response rate, with BBO-11818 and BBO-10203 data updates due in Q4 2026.


Key Events · Earnings and Guidance · BBOT

  • Q3 Loss Narrows Year Over Year

    Net loss was $34.2M for Q3 2026 versus $44.8M in Q3 2025, with R&D down to $29.6M from $35.1M and G&A down to $7.9M from $14.1M.

  • Cash Runway Extended Into 2029

    Cash, cash equivalents and marketable securities totaled $315.3M as of September 30, 2026, which the company expects to fund operations into 2029.

  • BBO-8520 Monotherapy 63% ORR

    In 2L+ KRAS G12C inhibitor-naive NSCLC, BBO-8520 monotherapy showed a 63% ORR (26/41) and 100% disease control rate (41/41), with no grade 3 or higher liver enzyme elevations.

  • Q4 2026 Data Updates Expected

    Monotherapy data updates for BBO-11818 and BBO-10203 are expected in the fourth quarter of 2026, with combination cohorts enrolling in CRC and PDAC.


Analysis · BBOT · Life Sciences

The quarter itself marks an improvement: net loss fell to $34.2M from $44.8M a year ago as R&D and G&A both came down, and the $315.3M cash balance now funds operations into 2029 rather than 2028. That buys roughly three more years of runway without needing to tap the $200M ATM set up in September—a critical cushion for a clinical-stage name burning cash. The clinical update is the other half of the story: BBO-8520 monotherapy showed a 63% response rate (26 of 41 patients) with every patient achieving disease control, and the combination data first reported in September is restated. Near-term, BBO-11818 and BBO-10203 monotherapy data updates are expected in the fourth quarter of 2026.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BBOT was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $176.4M. The 52-week trading range was $1.98 to $14.87. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BBOT - Latest Insights

BBOT
Nov 10, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $2.46 info
Change: +$0.280 (+13%) info
Market Cap: $197.229M info
BBOT
Sep 08, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.77
Real-time Price: $2.46 info
Change: -$6.31 (-72%) info
Market Cap: $197.229M info
BBOT
Aug 11, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $2.46 info
Change: -$6.74 (-73%) info
Market Cap: $197.229M info
BBOT
Aug 11, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $2.46 info
Change: -$6.74 (-73%) info
Market Cap: $197.229M info
BBOT
May 12, 2026, 5:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $8.13
Real-time Price: $2.46 info
Change: -$5.67 (-70%) info
Market Cap: $197.229M info